Catalyst Pharmaceuticals (CPRX) Reports Record Q4 and Full Year 2025 Results
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is one of the best cheap biotech stocks to buy now. Catalyst Pharmaceuticals, Inc.
Posts Tagged ‘NASDAQ:CPRX’
12 Cheap Biotech Stocks to Buy Now
In this article, we will look at the 12 Cheap Biotech Stocks to Buy Now.
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q4 2025 Earnings Call Transcript
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q4 2025 Earnings Call Transcript February 26, 2026 Operator: Good morning, and thank you for standing by.
Catalyst Pharmaceuticals, Inc. (CPRX): A Bull Case Theory
We came across a bullish thesis on Catalyst Pharmaceuticals, Inc. on BioEquity Watch’s Substack. In this article, we will summarize the bulls’ thesis on CPRX.
7 Stocks on Jim Cramer’s Radar Recently
Jim Cramer, the host of Mad Money, on Tuesday talked about the opening days of earnings season and the market’s uneven behavior. “The market gets so angry over nothing.
Analysts See Big Upside in Catalyst Pharmaceuticals, Inc. (CPRX)
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is among the cheap healthcare stocks to buy heading into 2026. As of December 7, Catalyst Pharmaceuticals, Inc.
12 Cheap Healthcare Stocks to Buy Heading into 2026
In this article, we will take a look at the cheap healthcare stocks to buy heading into 2026.
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q3 2025 Earnings Call Transcript
Catalyst Pharmaceuticals, Inc.
What do Analysts Think About Catalyst Pharmaceuticals (CPRX)?
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is one of the best biotech stocks with high potential. HC Wainwright reiterated a Buy rating on Catalyst Pharmaceuticals, Inc.
14 Biotech Stocks with High Potential
In this article, we will look at the top 14 Biotech Stocks with High Potential.
Catalyst Pharmaceuticals, Inc. (CPRX) Secures FIRDAPSE Market Exclusivity Until 2035
We recently compiled a list of the 11 Cheap Biotech Stocks to Buy According to Hedge Funds. Catalyst Pharmaceuticals, Inc. is placed sixth among them.
11 Cheap Biotech Stocks to Buy According to Hedge Funds
In this article, we will be taking a look at the 11 Cheap Biotech Stocks to Buy According to Hedge Funds.
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q2 2025 Earnings Call Transcript
Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q1 2025 Earnings Call Transcript
Catalyst Pharmaceuticals, Inc.
11 Stocks with Consistent Growth to Buy Now
In this article, we will unveil the top 11 stocks with consistent growth you want to buy now. The market is clouded by friction between trading partners.
11 Best Russell 2000 Stocks to Buy According to Wall Street Analysts
In this article, we will be looking into the 11 best Russell 2000 stocks that have garnered recommendations from Wall Street analysts.
What Makes Catalyst Pharmaceuticals (CPRX) an Investment Choice?
Renaissance Investment Management, an investment management company, released its Q4 2024 “Small Cap Growth Strategy” investor letter.
11 Best Gene Therapy Stocks to Buy According to Analysts
In this article, we will be taking a look at the 11 best gene therapy stocks to buy according to analysts.
Jim Cramer Discussed These 6 Stocks Recently
On Tuesday, Jim Cramer, host of Mad Money, defended the growing wave of artificial intelligence investment, drawing a distinct line between this boom and previous capital expenditure...
10 Best Healthcare Stocks For Long-Term Investment
In this article, we will be taking a look at the 10 best healthcare stocks for long-term investment.
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q4 2024 Earnings Call Transcript
Catalyst Pharmaceuticals, Inc.
10 Best Performing Biotech Stocks in 2024
In this article, we will be taking a look at the 10 best performing biotech stocks in 2024.
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q3 2024 Earnings Call Transcript
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q3 2024 Earnings Call Transcript November 7, 2024 Operator: Thank you for standing by.
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q2 2024 Earnings Call Transcript
Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q1 2024 Earnings Call Transcript
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q1 2024 Earnings Call Transcript May 9, 2024 Catalyst Pharmaceuticals, Inc.
Jim Cramer’s 10 Favorite Healthcare Stock Picks in 2024
In this article, we will take a detailed look at Jim Cramer’s 10 Favorite Healthcare Stock Picks in 2024.
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q4 2023 Earnings Call Transcript
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q4 2023 Earnings Call Transcript February 29, 2024 Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q3 2023 Earnings Call Transcript
Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q2 2023 Earnings Call Transcript
Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q1 2023 Earnings Call Transcript
Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q4 2022 Earnings Call Transcript
Catalyst Pharmaceuticals, Inc.
13 High Growth Pharma Stocks that are Profitable
In this piece, we will take a look at 13 high growth pharma stocks that are profitable.
12 Best Performing NASDAQ Stocks in 2022
In this article, we discuss 12 best performing NASDAQ stocks in 2022.
12 Best Performing Biotech Stocks in 2022
In this article, we discuss 12 best performing biotech stocks in 2022.
12 Best Small-Cap Healthcare Stocks To Buy Now
In this article, we discuss 12 best small-cap healthcare stocks to buy now.
10 Robinhood Stocks To Buy That Are Too Cheap To Ignore
In this article, we will be taking a look at 10 Robinhood stocks to buy that are too cheap to ignore.
10 Growth Stocks Under $20 in Billionaire Ken Fisher’s Portfolio
In this article, we discuss the 10 growth stocks under $20 in billionaire Ken Fisher's portfolio.
Here is What Hedge Funds Think About Catalyst Pharmaceuticals, Inc. (CPRX)
Hedge funds and other investment firms that we track manage billions of dollars of their wealthy clients' money, and needless to say, they are painstakingly thorough when analyzing...
Should You Buy Catalyst Pharmaceuticals, Inc. (CPRX)?
Hedge Funds and other institutional investors have just completed filing their 13Fs with the Securities and Exchange Commission, revealing their equity portfolios as of the end...
Catalyst Pharmaceuticals Inc (CPRX) and Achillion Pharmaceuticals, Inc. (ACHN) Among Five Cheap Healthcare Stocks To Buy Now
There are plenty of opportunities to invest in healthcare stocks, as there are thousands of companies, ranging from big and well-established pharmaceuticals that also pay substantial...
Here’s Why Traders Are Piling Into These Five Stocks
All three major indexes are in the green today as investors look forward to today's FOMC meeting decision.
Here’s Why Catalyst Pharmaceuticals, Resolute Energy, Nutanix & Two Other Stocks Are Trading Higher Today
The markets have shaken off their negative trend as major indices are trading in the green zone.
Noteworthy Insider Transactions at 5 Companies Amid Slowing Insider Buying as Markets Near All-Time Highs
Investors usually associate insider trading with illegal conduct, but not all insider trading activity is illegal.
Most Popular Healthcare Penny Stocks Among Hedge Funds
Although a great movie, The Wolf of Wall Street left many people thinking penny stocks are somewhat 'untouchable'.
What Has Investors Spooked About These 5 Stocks Today?
Although all three indexes are in the green and crude futures are 2% higher, shares of Capital Product Partners L.P.
Insider Buying Points To Huge Upside For These 3 Beaten-Down Stocks
Rising interest rates, a struggling Chinese economy, declining crude oil prices and a strong U.S dollar are key factors that explain the increased volatility and wild swings in...
Is Catalyst Pharmaceutical Partners, Inc. (CPRX) a “Buy” after Its Promising Results In Proof-Of-Concept Trial Of Vigabatrin
Earlier today Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) has announced promising top-line results in proof-of-concept trial of its CPP-109 (Vigabatrin).
Catalyst Pharmaceutical Partners, Inc. (CPRX): Steven Cohen Bets on Another Biotech Development-Stage Stock
In a new filing with the Securities and Exchange Commission, Steven Cohen's Point72 Asset Management disclosed a new stake in Catalyst Pharmaceutical Partners, Inc.
Hedge Fund Resource Center
